Metabolomics as a tool for personalizing medicine: 2012 update

Personalized Medicine

Volumn 10, Issue 2, 2013, Pages 149-161

  Sun, Jinchun ^a   Beger, Richard D ^a   Schnackenberg, Laura K ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

biomarkers; metabolomics; personalized medicine; pharmacogenetics; pharmacometabolomics

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; DOCETAXEL; ESCITALOPRAM; PARACETAMOL; TACROLIMUS; XIMELAGATRAN;

ALZHEIMER DISEASE; CANCER THERAPY; CHEMOMETRICS; DIET; DISEASE COURSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEVEA BRASILIENSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUTRITION; PEDIATRICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; POLYPHARMACY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84874622172     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.8     Document Type: Review

References (80)

1. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl Acad. Sci. USA 68(10), 2374-2376 (1971).
2. Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. J. Cell. Physiol. 227(8), 2975-2981 (2012).
3. Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. Trends Anal. Chem. 24(4), 285-294 (2005).
4. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J. Proteome Res. 6(2), 443-458 (2007).
5. Robertson DG, Watkins PB, Reily MD. Metabolomics in toxicology: preclinical and clinical applications. Toxicol. Sci. 120(Suppl. 1), S146-S170 (2011).
6. Becquemont L, Alfirevic A, Amstutz U et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12(1), 113-124 (2011).
7. Cecchin E, Agostini M, Pucciarelli S et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 11(3), 214-226 (2011).
8. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol. Diagn. Ther. 13(1), 1-9 (2009).
9. Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a Phase I dose-escalation study. J. Clin. Oncol. 28(7), 1181-1189 (2010).
10. Benhaim L, Labonte MJ, Lenz HJ. Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives. Scand. J. Gastroenterol. 47(3), 325-339 (2012).
11. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol. 3, 124 (2007).
12. Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl Acad. Sci. USA 106(34), 14187-14188 (2009).
13. Nicholson JK, Wilson ID, Lindon JC. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12(1), 103-111 (2011).
14. Nicholson JK, Everett JR, Lindon JC. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin. Drug Metab. Toxicol. 8(2), 135-139 (2012).
15. Li F, Lu J, Ma X. Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem. Res. Toxicol. 24(12), 2109-2114 (2011).
16. Sun J, Schnackenberg LK, Beger RD. Studies of acetaminophen and metabolites in urine and their correlations with toxicity using metabolomics. Drug Metab. Lett. 3(3), 130-136 (2009).
17. Sun J, Schnackenberg LK, Hansen DK, Beger RD. Study of valproic acid-induced endogenous and exogenous metabolite alterations using LC-MS-based metabolomics. Bioanalysis 2(2), 207-216 (2010).
18. Monte AA, Heard KJ, Vasiliou V. Prediction of drug response and safety in clinical practice. J. Med. Toxicol. 8(1), 43-51 (2012).
19. Phapale PB, Kim SD, Lee HW et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin. Pharmacol. Ther. 87(4), 426-436 (2010).
20. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29(6), 404-430 (1995).
21. Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006).
22. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106(34), 14728-14733 (2009).
23. Winnike JH, Li Z, Wright FA et al. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88(1), 45-51 (2010).
24. Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8(3), 186-195 (2008).
25. Andersson U, Lindberg J, Wang S et al. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 14(8), 572-586 (2009).
26. Ji Y, Hebbring S, Zhu H et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 89(1), 97-104 (2011).
27. Kaddurah-Daouk R, Baillie RA, Zhu H et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6(2), 191-201 (2010).
28. Oakman C, Tenori L, Claudino WM et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 22(6), 1295-1301 (2011).
29. Kaddurah-Daouk R, Baillie RA, Zhu H et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6(10), e25482 (2011).
30. Trupp M, Zhu H, Wikoff WR et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS ONE 7(7), e38386 (2012).
31. Connolly JJ, Hakonarson H. The impact of genomics on pediatric research and medicine. Pediatrics 129(6), 1150-1160 (2012).
32. Adamski J. Genome-wide association studies with metabolomics. Genome Med. 4(4), 34 (2012).
33. Robinette SL, Holmes E, Nicholson JK, Dumas ME. Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations. Genome Med. 4(4), 30 (2012).
34. Altmaier E, Kastenmuller G, Romisch-Margl W et al. Questionnaire-based self-reported nutrition habits associate with serum metabolism as revealed by quantitative targeted metabolomics. Eur. J. Epidemiol. 26(2), 145-156 (2011).
35. Altmaier E, Ramsay SL, Graber A et al. Bioinformatics analysis of targeted metabolomics-uncovering old and new tales of diabetic mice under medication. Endocrinology 149(6), 3478-3489 (2008).
36. Suhre K, Romisch-Margl W, de Angelis MH et al. Identification of a potential biomarker for FABP4 inhibition: the power of lipidomics in preclinical drug testing. J. Biomol. Screen. 16(5), 467-475 (2011).
37. Wang-Sattler R, Yu Y, Mittelstrass K et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans-first results from the KORA study. PLoS ONE 3(12), e3863 (2008).
38. Petersen AK, Krumsiek J, Wagele B et al. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinformatics 13(1), 120 (2012).
39. Suhre K, Meisinger C, Doring A et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5(11), e13953 (2010).
40. Suhre K, Wallaschofski H, Raffler J et al. A genome-wide association study of metabolic traits in human urine. Nat. Genet. 43(6), 565-569 (2011).
41. Ala-Korpela M, Kangas AJ, Soininen P. Quantitative high-throughput metabolomics: a new era in epidemiology and genetics. Genome Med. 4(4), 36 (2012).
42. Nordström A, Lewensohn R. Metabolomics: moving to the clinic. J. Neuroimmune Pharmacol. 5(1), 4-17 (2010).
43. Mendrick DL, Schnackenberg L. Genomic and metabolomic advances in the identification of disease and adverse event biomarkers. Biomark. Med. 3(5), 605-615 (2009).
44. Kwon HN, Kim M, Wen H et al. Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach. Kidney Int. 79(5), 529-537 (2011).
45. Bayet-Robert M, Morvan D, Chollet P, Barthomeuf C. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res. Treat. 120(3), 613-626 (2010).
46. Backshall A, Sharma R, Clarke SJ, Keun HC. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin. Cancer Res. 17(9), 3019-3028 (2011).
47. Lodi A, Ronen SM. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS ONE 6(10), e26155 (2011).
48. Iles RA, Hind AJ, Chalmers RA. Use of proton nuclear magnetic resonance spectroscopy in detection and study of organic acidurias. Clin. Chem. 31(11), 1795-1801 (1985).
49. 1H-FT-NMR spectrometry. Eur. J. Pediatr. 145(4), 260-266 (1986).
50. Yamamoto H, Koda N. Revised method of 1H-NMR urinalysis for detecting inborn errors of metabolism. Clin. Chem. 33(5), 714-715 (1987).
51. Wikoff WR, Gangoiti JA, Barshop BA, Siuzdak G. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin. Chem. 53(12), 2169-2176 (2007).
52. Kawashima H, Oguchi M, Ioi H et al. Primary biomarkers in cerebral spinal fluid obtained from patients with influenza-associated encephalopathy analyzed by metabolomics. Int. J. Neurosci. 116(8), 927-936 (2006).
53. Baraldi E, Carraro S, Giordano G et al. Metabolomics: moving towards personalized medicine. Ital. J. Pediatr. 35(1), 30 (2009).
54. Wolak JE, Esther CR Jr, O'Connell TM. Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers 14(1), 55-60 (2009).
55. Beger RD, Holland RD, Sun J et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr. Nephrol. 23(6), 977-984 (2008).
56. Oresic M, Simell S, Sysi-Aho M et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to Type 1 diabetes. J. Exp. Med. 205(13), 2975-2984 (2008).
57. Martinez-Outschoorn UE, Prisco M, Ertel A et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics. Cell Cycle 10(8), 1271-1286 (2011).
58. Ekroos K, Janis M, Tarasov K, Hurme R, Laaksonen R. Lipidomics: a tool for studies of atherosclerosis. Curr. Atheroscler. Rep. 12(4), 273-281 (2010).
59. McClay JL, Adkins DE, Isern NG et al. (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J. Proteome Res. 9(6), 3083-3090 (2010).
60. Glocker MO, Guthke R, Kekow J, Thiesen HJ. Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine. Med. Res. Rev. 26(1), 63-87 (2006).
61. Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J. Proteome Res. 6(9), 3456-3464 (2007).
62. van Wietmarschen H, Yuan K, Lu C et al. Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. J. Clin. Rheumatol. 15(7), 330-337 (2009).
63. van Wietmarschen HA, Dai W, van der Kooij AJ et al. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS ONE 7(9), e44331 (2012).
64. Muller G. Personalized prognosis and diagnosis of Type 2 diabetes-vision or fiction? Pharmacology 85(3), 168-187 (2010).
65. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol. Sci. 26(11), 558-563 (2005).
66. Wei H, Pasman W, Rubingh C et al. Urine metabolomics combined with the personalized diagnosis guided by Chinese medicine reveals subtypes of pre-diabetes. Mol. Biosyst. 8(5), 1482-1491 (2012).
67. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17(4), 448-453 (2011).
68. Huang CF, Cheng ML, Fan CM, Hong CY, Shiao MS. Nicotinuric acid: a potential marker of metabolic syndrome through a metabolomics-based approach. Diabetes Care doi:10.2337/dc12-1067 (2012) (Epub ahead of print).
69. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 1012(1-2), 60-65 (2004).
70. Marjanska M, Curran GL, Wengenack TM et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl Acad. Sci. USA 102(33), 11906-11910 (2005).
71. Kantarci K, Weigand SD, Petersen RC et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 28(9), 1330-1339 (2007).
72. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 355(9216), 1696-1697 (2000).
73. Block W, Jessen F, Traber F et al. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch. Neurol. 59(5), 828-834 (2002).
74. Rami L, Gomez-Anson B, Bosch B et al. Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 24(4), 274-279 (2007).
75. Shonk TK, Moats RA, Gifford P et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195(1), 65-72 (1995).
76. Choi JK, Dedeoglu A, Jenkins BG. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed. 20(3), 216-237 (2007).
77. Klunk WE, Xu C, Panchalingam K, McClure RJ, Pettegrew JW. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 17(3), 349-357 (1996).
78. Miller BL, Moats RA, Shonk T et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187(2), 433-437 (1993).
79. Pettegrew JW, Klunk WE, Panchalingam K, McClure RJ, Stanley JA. Magnetic resonance spectroscopic changes in Alzheimer's disease. Ann. NY Acad. Sci. 826, 282-306 (1997).
80. Chen R, Mias G, Li-Pook-Than J et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148(6), 1293-1307 (2012).